What target hemoglobin range is recommended by KDOQI for patients receiving erythropoiesis-stimulating agents?

The correct target hemoglobin range recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) for patients receiving erythropoiesis-stimulating agents is 11.0-12.0 g/dL. This range is endorsed to improve outcomes in patients with chronic kidney disease who require management of anemia.

Maintaining hemoglobin levels within this target range helps to reduce the risks associated with anemia and its adverse effects, including fatigue, cardiovascular issues, and impaired quality of life. It is crucial for nephrologists and healthcare providers to monitor hemoglobin closely in patients receiving erythropoiesis-stimulating agents, as achieving levels too low may lead to anemia-related complications, while excessively high levels can increase the risk for adverse cardiovascular events. Therefore, the recommended target helps to balance the benefits of treatment with these potential risks, promoting optimal patient care.